EGFR and glioblastoma: In further support of this strategy, a recent study shows that intracranial delivery of toxin-conjugated scFv from an EGFR antibody targeting both wtEGFR and EGFRvIII results in strong anti-neoplastic effects against intracranial glioblastoma xenografts expressing wtEGFR or co-expressing wtEGFR and EGFRvIII.